Skip to Content

Sanofi SA ADR

SNY: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$27.00LmcXtsypjd

Sanofi Earnings: Solid Results Led by Robust Dupixent Sales and Investments in the Pipeline

Sanofi reported solid first-quarter results largely in line with our expectations and we're holding firm to our fair value. We continue to view the stock as undervalued with the market not fully appreciating Sanofi’s long-term growth potential and developing pipeline that also reinforces the firm’s wide moat.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of SNY so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center